Prolonged anti-CD40 ligand therapy improves primate cardiac allograft survival

被引：12

作者：

Chang, AC

Blum, MG

Blair, KSA

Scott, MA

Brock, JE

Thomas, DW

Burkly, LC

Miller, GG

Pierson, RN

机构：

[1] Vanderbilt Univ, Med Ctr, Vanderbilt Clin, Nashville, TN 37232 USA

[2] Biogen Inc, Cambridge, MA 02142 USA

来源：

TRANSPLANTATION PROCEEDINGS | 1999年 / 31卷 / 1-2期

关键词：

D O I：

10.1016/S0041-1345(98)01455-9

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：95 / 95

页数：1

共 4 条

[1]

CHANG AC, 1997, 23 ANN SCI M AM SOC

[2] Immune regulation by CD40 and its ligand GP39 [J].

Foy, TM ;

Aruffo, A ;

Bajorath, J ;

Buhlmann, JE ;

Noelle, RJ .

ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :591-617

[3] CTLA4-Ig and anti-CD4O ligand prevent renal allograft rejection in primates [J].

Kirk, AD ;

Harlan, DM ;

Armstrong, NN ;

Davis, TA ;

Dong, YC ;

Gray, GS ;

Hong, XN ;

Thomas, D ;

Fechner, JH ;

Knechtle, SJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) :8789-8794

[4] CD40-gp39 interactions play a critical role during allograft rejection - Suppression of allograft rejection by blockade of the CD40-gp39 pathway [J].

Larsen, CP ;

Alexander, DZ ;

Hollenbaugh, D ;

Elwood, ET ;

Ritchie, SC ;

Aruffo, A ;

Hendrix, R ;

Pearson, TC .

TRANSPLANTATION, 1996, 61 (01) :4-9

← 1 →